In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The 14 Billion Dose COVID-19 Manufacturing Challenge

mRNA Vaccines Leading The Way

Executive Summary

Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.

You may also be interested in...



Pfizer Rose To The COVID-19 Challenge And The Stars Aligned

Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.

Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch

The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.

Sanofi Adds mRNA Specialist Tidal To Acquisition Spree

Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel